Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mistry

Showing results (211-220 of 237) with videos related to

Pageof 24
Sort By:
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Plos One|September 18, 2015
The Role of ARF6 in Biliary AtresiaMylarappa Ningappa, Juhoon So, Joseph Glessner, et al.
Ebiomedicine|August 11, 2023
Advancing diagnosis and management of liver disease in adults through exome sequencingMelanie Zheng, Aaron Hakim, Chigoziri Konkwo, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Journal of Inherited Metabolic Disease|May 30, 2008
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringT M Cox, J M F G Aerts, N Belmatoug, et al.
Journal of Inherited Metabolic Disease|February 10, 2018
Hepatocellular carcinoma in Gaucher disease: an international case seriesMartine Regenboog, Laura van Dussen, Joanne Verheij, et al.
Blood|August 27, 2011
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic responseNick Dekker, Laura van Dussen, Carla E M Hollak, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
American Journal of Human Genetics|January 22, 2013
Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticityMonia B Hammer, Ghada Eleuch-Fayache, Lucia V Schottlaender, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
Pageof 24

Showing results (211-220 of 237) with videos related to

Sort By:
Pageof 24
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Plos One|September 18, 2015
The Role of ARF6 in Biliary AtresiaMylarappa Ningappa, Juhoon So, Joseph Glessner, et al.
Ebiomedicine|August 11, 2023
Advancing diagnosis and management of liver disease in adults through exome sequencingMelanie Zheng, Aaron Hakim, Chigoziri Konkwo, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Journal of Inherited Metabolic Disease|May 30, 2008
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringT M Cox, J M F G Aerts, N Belmatoug, et al.
Journal of Inherited Metabolic Disease|February 10, 2018
Hepatocellular carcinoma in Gaucher disease: an international case seriesMartine Regenboog, Laura van Dussen, Joanne Verheij, et al.
Blood|August 27, 2011
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic responseNick Dekker, Laura van Dussen, Carla E M Hollak, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
American Journal of Human Genetics|January 22, 2013
Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticityMonia B Hammer, Ghada Eleuch-Fayache, Lucia V Schottlaender, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
Pageof 24